ClinicalTrials.gg
CompletedNCT02659514Updated Mar 11, 2022Results posted

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

A Phase 2 interventional study of Poziotinib in Breast Cancer, sponsored by Spectrum Pharmaceuticals, Inc. Completed at 35 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2022-03-11.

Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
67
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Breast Neoplasms by Zydus Lifesciences Limited — none open to participants now, none under way, none of them phase 3. Breast Neoplasms · Zydus Lifesciences Limited.

Enrollment
5th of 10
67 · median 63
Started
2016
with 1 other
Phase 2
3 of 10
none open now
Registered
3rd of 10
by date

Among the 10 studies in Breast Neoplasms by Zydus Lifesciences Limited, this one is the 5th largest by enrollment, is one of 2 that started in 2016, is one of 3 in phase 2, and was the 3rd registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

None of the 10 studies in Breast Neoplasms by Zydus Lifesciences Limited is open now. The open studies under Breast Neoplasms, anywhere →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Breast Neoplasms by Zydus Lifesciences Limited as a file.
02

Study summary

The purpose of this study is to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer who have received at least two prior HER2-directed treatment regimens.

Read the detailed description

This is a phase 2, open-label, multicenter study to establish the dose regimen and evaluate the preliminary efficacy and the safety/tolerability of poziotinib in participants with HER2-positive metastatic breast cancer who have received at least two prior HER2-directed treatment regimens.

Each treatment cycle will be 21 days in duration. During each 21-day cycle, participants who are eligible for participation will receive poziotinib orally once daily.

All treated participants will be followed up until disease progression, death, intolerable adverse events or up to a maximum of 24 months whichever comes earlier.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Poziotinib
  • Metastatic Breast Cancer
  • HER2-positive
  • Pan-HER inhibitor
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Histopathologically confirmed primary breast cancer with lesions.
  2. Confirmed overexpression or gene-amplified tumor
  3. At least two prior HER2-directed therapy regimens for breast cancer, including trastuzumab and trastuzumab emtansine
  4. per Response Evaluation Criteria for Solid Tumors version 1.1 ( v1.1)
  5. Participant is at least 18, and ≤90 years of age.
  6. Adequate hematologic, hepatic, and renal function
  7. (ECOG) performance status \<= 2

Exclusion criteria

Exclusion Criteria:

  1. Previous treatment with poziotinib prior to study participation
  2. that are symptomatic or require therapy to control symptoms, as well as any history of radiation, surgery, or other therapy, including , to control symptoms from brain metastases within 15 days of enrollment.
  3. Anticancer chemotherapy, biologics, immunotherapy, cure-intent radiotherapy, or treatment within 15 days, except for hormone therapy, palliative therapy, or supportive therapy.
  4. History of congestive heart failure Class III/IV according to the (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment.
  5. Cardiac \<50%
  6. History of other within the last 5 years
  7. Participant is pregnant or breast-feeding.
  8. Unable to take drugs orally
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
67 participants (actual)

Study arms

  • Experimental
    Cohort 1: Poziotinib 24 mg

    Participants received poziotinib 24 milligrams (mg), administered as three 8 mg tablets, orally, once daily (QD) on an intermittent dosing schedule of 14 days on treatment followed by 7 days off treatment, in a 21-day cycle until disease progression, death, intolerable adverse events (AEs) or for up to a maximum of 24 months, whichever occurs first.

    Drug: Poziotinib

  • Experimental
    Cohort 2: Poziotinib 16 mg

    Participants received poziotinib 16 mg, administered as two 8 mg tablets, orally, QD, on a continuous dosing schedule in a 21-day cycle until disease progression, death, intolerable AEs or for up to a maximum of 24 months, whichever occurs first.

    Drug: Poziotinib

Interventions

  • 8 mg oral tablets, administered QD.

    Also known as: HM781-36B

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    ORR was defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) among participants in the Evaluable Population assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR was based on investigator assessed BOR. Per RECIST v1.1 for target lesions, CR was disappearance of all target tumor lesions (TLs) and all target lymph nodes (LNs) with short axis \<10mm. PR was ≥30% decrease in sum of diameters (SOD) from Baseline, and not progressive disease (PD) (≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm).

    Time frame: Up to 24 months

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS was the duration of time (in months) from first administration of study treatment to date of first documented disease progression or death from any cause. PFS of living participants without documented PD was censored at the time of last tumor assessment or the date of first treatment if there was no post-baseline tumor assessment. Per RECIST v1.1 for target lesions, PD was defined as ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm.

    Time frame: Up to 24 Months

  2. Disease Control Rate (DCR)

    DCR was the percentage of participants whose best response was CR, PR or stable disease (SD) among participants in the Evaluable Population assessed per RECIST v1.1. DCR was based on investigator-assessed BOR. Per RECIST v1.1 for target lesions, CR was defined as disappearance of all target TLs and all target LNs with short axis \<10mm. PR was ≥30% decrease in sum of diameters (SOD) from Baseline, and not progressive disease (≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm). SD was SOD change neither sufficient for PR nor sufficient for PD.

    Time frame: Up to 24 months

  3. Time to Progression (TTP)

    TTP was defined as the time (in months) from first administration of study drug to tumor progression, which excluded death without tumor progression, by the end of study. TTP of participants who died without documented PD was censored at date of death. TTP of living participants without documented PD was censored at the same time as PFS, which was the last tumor assessment or the date of first treatment if there was no post-baseline tumor assessment. Per RECIST v1.1 for target lesions, PD was defined as ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm.

    Time frame: Up to 24 months

  4. Duration of Response (DoR)

    DoR was evaluated only for participants whose BOR was CR or PR and was defined as the time (in months) from the date that response evaluation criteria were first met for CR or PR (whichever status was recorded first) until the first subsequent date that PD or death was documented. DoR of participants without documented PD or death was censored at the time of last tumor assessment. Per RECIST v1.1 for target lesions, CR was defined as disappearance of all target tumor lesions (TLs) and all target lymph nodes (LNs) with short axis \<10mm. PR was defined as ≥30% decrease in sum of diameters (SOD) from Baseline, and not PD. PD was defined as ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm).

    Time frame: Up to 24 months

  5. Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)

    An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were AEs that occurred or worsened from the first dose of study treatment until 35 (± 5) days after the last dose of study treatment.

    Time frame: From the first dose of study drug administration until 35 (± 5) days after the last dose of study drug administration (Up to approximately 25 months)

  6. Pharmacokinetic Analysis (Drug Concentration Measurements)

    Time frame: For Cohort 1: Pre-dose and 1 and 2 hours post-dose on Day 1 of Cycles 1, 2, and 3, and pre-dose on Day 14 of Cycle 1 For Cohort 2: Day 1 of Cycle 1 pre-dose and 30 minutes, 1,1.5,2,3, 4, 6, and 24 hours post-dose of Day 1 of Cycle 1

07

Results

Posted Feb 10, 2022

Participant flow

A total of 67 participants were enrolled at 19 sites in the United States in the study which was conducted from 22 February 2016 to 11 March 2020.

Participant flow — Overall Study
MilestoneCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Started3334
Safety population3334
Evaluable population3027
Completed10
Not completed3234
Withdrew: Adverse event312
Withdrew: Disease progression2313
Withdrew: Withdrawal by subject04
Withdrew: Lost to follow-up01
Withdrew: Death61
Withdrew: Reason unspecified03

Outcome measures

PrimaryObjective Response Rate (ORR)

ORR was defined as the percentage of participants whose best overall response (BOR) was complete response (CR) or partial response (PR) among participants in the Evaluable Population assessed per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). ORR was based on investigator assessed BOR. Per RECIST v1.1 for target lesions, CR was disappearance of all target tumor lesions (TLs) and all target lymph nodes (LNs) with short axis \<10mm. PR was ≥30% decrease in sum of diameters (SOD) from Baseline, and not progressive disease (PD) (≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm).

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Objective Response Rate (ORR)30 (14.7 to 49.4)30 (13.8 to 50.2)
SecondaryProgression Free Survival (PFS)

PFS was the duration of time (in months) from first administration of study treatment to date of first documented disease progression or death from any cause. PFS of living participants without documented PD was censored at the time of last tumor assessment or the date of first treatment if there was no post-baseline tumor assessment. Per RECIST v1.1 for target lesions, PD was defined as ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm.

Time frame:
Up to 24 Months
Reported as:
Median · months
Progression Free Survival (PFS)
monthsCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Progression Free Survival (PFS)4.1 (1.5 to 5.6)4.9 (1.8 to 7.4)
SecondaryDisease Control Rate (DCR)

DCR was the percentage of participants whose best response was CR, PR or stable disease (SD) among participants in the Evaluable Population assessed per RECIST v1.1. DCR was based on investigator-assessed BOR. Per RECIST v1.1 for target lesions, CR was defined as disappearance of all target TLs and all target LNs with short axis \<10mm. PR was ≥30% decrease in sum of diameters (SOD) from Baseline, and not progressive disease (≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm). SD was SOD change neither sufficient for PR nor sufficient for PD.

Time frame:
Up to 24 months
Reported as:
Number · percentage of participants
Disease Control Rate (DCR)
percentage of participantsCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Disease Control Rate (DCR)60 (40.6 to 77.3)78 (57.7 to 91.4)
SecondaryTime to Progression (TTP)

TTP was defined as the time (in months) from first administration of study drug to tumor progression, which excluded death without tumor progression, by the end of study. TTP of participants who died without documented PD was censored at date of death. TTP of living participants without documented PD was censored at the same time as PFS, which was the last tumor assessment or the date of first treatment if there was no post-baseline tumor assessment. Per RECIST v1.1 for target lesions, PD was defined as ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm.

Time frame:
Up to 24 months
Reported as:
Median · months
Time to Progression (TTP)
monthsCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Time to Progression (TTP)4.1 (1.5 to 5.6)4.9 (1.8 to 7.4)
SecondaryDuration of Response (DoR)

DoR was evaluated only for participants whose BOR was CR or PR and was defined as the time (in months) from the date that response evaluation criteria were first met for CR or PR (whichever status was recorded first) until the first subsequent date that PD or death was documented. DoR of participants without documented PD or death was censored at the time of last tumor assessment. Per RECIST v1.1 for target lesions, CR was defined as disappearance of all target tumor lesions (TLs) and all target lymph nodes (LNs) with short axis \<10mm. PR was defined as ≥30% decrease in sum of diameters (SOD) from Baseline, and not PD. PD was defined as ≥20% increase in SOD from previous smallest SOD on study, and an absolute increase of ≥5mm).

Time frame:
Up to 24 months
Reported as:
Median · months
Duration of Response (DoR)
monthsCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Duration of Response (DoR)5.7 (1.8 to NA)13.0 (2.2 to NA)
SecondaryNumber of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)

An AE was defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAEs were AEs that occurred or worsened from the first dose of study treatment until 35 (± 5) days after the last dose of study treatment.

Time frame:
From the first dose of study drug administration until 35 (± 5) days after the last dose of study drug administration (Up to approximately 25 months)
Reported as:
Number · participants
Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)
participantsCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs)3333
SecondaryPharmacokinetic Analysis (Drug Concentration Measurements)
Time frame:
For Cohort 1: Pre-dose and 1 and 2 hours post-dose on Day 1 of Cycles 1, 2, and 3, and pre-dose on Day 14 of Cycle 1 For Cohort 2: Day 1 of Cycle 1 pre-dose and 30 minutes, 1,1.5,2,3, 4, 6, and 24 hours post-dose of Day 1 of Cycle 1

No measurements were reported for this outcome.

Adverse events

Collected over All-Cause Mortality: From the first dose of study drug administration up to approximately 48.5 months; Serious and Other Adverse Events: From the first dose of study drug administration until 35 (± 5) days after the last dose of study drug administration (up to approximately 25 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Poziotinib 24 mg6/33 (18.2%)14/33 (42.4%)33/33 (100%)
Cohort 2: Poziotinib 16 mg1/34 (2.9%)16/34 (47.1%)33/34 (97.1%)
Most frequent serious events
Showing 10 of 32
Most frequent serious events
EventCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
DiarrhoeaGastrointestinal disorders6/332/34
DehydrationMetabolism and nutrition disorders2/332/34
BacteraemiaInfections and infestations0/332/34
Cardio-respiratory arrestCardiac disorders1/330/34
VomitingGastrointestinal disorders1/330/34
AstheniaGeneral disorders1/330/34
PneumoniaInfections and infestations1/330/34
Soft tissue infectionInfections and infestations1/330/34
Femur fractureInjury, poisoning and procedural complications1/330/34
Haemorrhage intracranialNervous system disorders1/330/34
Most frequent other events
Showing 10 of 233
Most frequent other events
EventCohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mg
DiarrhoeaGastrointestinal disorders30/3329/34
RashSkin and subcutaneous tissue disorders20/3315/34
FatigueGeneral disorders18/3317/34
StomatitisGastrointestinal disorders16/3317/34
NauseaGastrointestinal disorders12/3317/34
VomitingGastrointestinal disorders16/3311/34
Decreased AppetiteMetabolism and nutrition disorders13/3316/34
HypokalaemiaMetabolism and nutrition disorders7/3312/34
Dry skinSkin and subcutaneous tissue disorders11/336/34
Dermatitis acneiformSkin and subcutaneous tissue disorders8/3310/34

Baseline characteristics

Safety population included all participants who received at least 1 dose of poziotinib.

Age, Continuous
Age, Continuous(years)Cohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mgTotal
Mean56.4 ± 13.8258.1 ± 11.1057.3 ± 12.45
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mgTotal
Female333467
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mgTotal
Hispanic or Latino5510
Not Hispanic or Latino282957
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mgTotal
American Indian or Alaska Native000
Asian202
Native Hawaiian or Other Pacific Islander011
Black or African American145
White302959
More than one race000
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort 1: Poziotinib 24 mgCohort 2: Poziotinib 16 mgTotal
Asian202
Native Hawaiian or Other Pacific Islander011
Black or African American145
White302959
08

Study locations

35 sites
  • Clearview Cancer Center
    Huntsville, Alabama 35805, United States
  • Pacific Cancer Medical Center, Inc.
    Anaheim, California 92801, United States
  • Marin Cancer Care, Inc
    Greenbrae, California 94904, United States
  • Alliance Research Centers
    Laguna Hills, California 92653, United States
  • PacificShores Medical Group
    Long Beach, California 90813, United States
  • Valley Medical Oncology Consultants
    Pleasanton, California 94588, United States
  • Innovative Clinical Research Institute
    Whittier, California 90603, United States
  • AMPM Research Clinic
    Miami Gardens, Florida 33169, United States
  • FL Cancer Research Institute
    Plantation, Florida 33324, United States
  • Bond Clinic, P.A.
    Winter Haven, Florida 33880, United States
  • Triple Army Medical Cente
    Honolulu, Hawaii 96859, United States
  • Franciscan St. Francis Health
    Indianapolis, Indiana 46237, United States
  • The University of Kansas Cancer Center and Medical Pavilion
    Westwood, Kansas 66205, United States
  • Hattiesburg Clinic Hematology Oncology
    Hattiesburg, Mississippi 39401, United States
  • Washington University
    Saint Louis, Missouri 63110, United States
  • St. Vincent Frontier Cancer Center
    Billings, Montana 59102, United States
  • North Shore Hematology Oncology Associates
    East Setauket, New York 11733, United States
  • Hudson Valley Hematology Oncology Associates
    Poughkeepsie, New York 12601, United States
  • White Plain Hospital
    White Plains, New York 10601, United States
  • Waverly Hematology Oncology
    Cary, North Carolina 27518, United States
  • Aultman Hospital
    Canton, Ohio 44710, United States
  • Ohio State University
    Columbus, Ohio 43210, United States
  • Oklahoma Cancer Specialists & Research Institute, LLC
    Tulsa, Oklahoma 74146, United States
  • Magee Womens Hospital of UPMC
    Pittsburgh, Pennsylvania 15213, United States
  • Charleston Cancer Center
    Charleston, South Carolina 29406, United States
  • Carolina Blood and Cancer Care Associates PA
    Rock Hill, South Carolina 29732, United States
  • Oncology Consultants, P.A.
    Houston, Texas 77030, United States
  • SAMMC - Hem/Onc Clinic
    Houston, Texas 78234, United States
  • Texas Oncology-McAllen
    McAllen, Texas 78503, United States
  • The University of Texas Health Science Center at San Antonio
    San Antonio, Texas 78229, United States
  • Scott & White Memorial Hospital
    Temple, Texas 76508, United States
  • Providence Regional Cancer System
    Lacey, Washington 98503, United States
  • Medical Oncology Associates, PS
    Spokane, Washington 99208, United States
  • Northwest Medical Specialties, PLLC
    Tacoma, Washington 98405, United States
  • West Virginia University
    Morgantown, West Virginia 26506, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2016 to primary completion in Mar 2020, 48 months.

Results were first posted in Feb 2022, 1 year 10 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 48 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2016
First posted
Jan 20, 2016
StartActual
Feb 22, 2016
Primary completionActual
Mar 11, 2020
CompletionActual
Mar 11, 2020
Results first posted
Feb 10, 2022
Last update
Mar 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02659514
Responsible party
Sponsor
First posted
Jan 20, 2016
Start date
Feb 22, 2016
Primary completion
Mar 11, 2020
Completion
Mar 11, 2020
Results posted
Feb 10, 2022
Last update
Mar 11, 2022

Study contacts

Shanta Chawla, MD
study director · Spectrum Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poziotinib

Start the discussion